NCT01833923View on ClinicalTrials.gov

A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Advanced Cancer
Interventions
DRUG

anlotinib

oral medicine.

Trial Locations (1)

100021

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

Sponsors
All Listed Sponsors
collaborator

Nanjing Medical University

OTHER

lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY